| CD70 molecule | |
|---|---|
| Identifiers | |
| Symbol | CD70 |
| Alt. symbols | CD27LG, TNFSF7 |
| Entrez | 970 |
| HUGO | 11937 |
| OMIM | 602840 |
| RefSeq | NM_001252 |
| UniProt | P32970 |
| Other data | |
| Locus | Chr. 19 p13 |
CD70 (Cluster of Differentiation 70) is a ligand for CD27.
The CD70 protein is expressed on highly activated lymphocytes (like in T- and B-cell lymphomas). It is therefore suggested that anti-CD70 antibodies might be a possible treatment for CD70 positive lymphomas as normal lymphocytes have low CD70 expression.
ARGX-110 is a CD70-specific antibody that is currently under investigation for the treatment of hematological malignancies. It is being developed by the Belgian company arGEN-X. In December 2013 a first part of a phase 1b trial was completed. In January 2014 a safety and efficacy phase of the study started.
Vorsetuzumab mafodotin is a CD70-targeted antibody-drug conjugate that started clinical trials for renal cell carcinoma.